Diffuse Alveolar Hemorrhage (DAH) After Alemtuzumab
The most likely cause of shortness of breath and hemoptysis after the third alemtuzumab dose is diffuse alveolar hemorrhage (DAH), a recognized serious adverse reaction that typically occurs early in treatment (within the first cycle) and requires immediate evaluation and supportive management.
Clinical Presentation and Mechanism
DAH is a well-documented complication of alemtuzumab therapy that presents with the classic triad you're observing:
- Acute shortness of breath (dyspnea)
- Hemoptysis
- Chest discomfort/pain
This reaction occurs as an early complication, typically during the first treatment cycle 1, 2, 3. The mechanism appears related to alemtuzumab's anti-CD52 activity causing immune-mediated pulmonary capillary damage, though the exact pathophysiology remains incompletely understood 4.
Diagnostic Approach
Immediate imaging and bronchoscopy are essential:
- CT chest: Look for diffuse bilateral ground-glass opacities, which are the hallmark finding 2, 3
- Bronchoscopy with BAL: Expect progressively bloodier return in sequential aliquots (characteristic of DAH), with no evidence of infection 3, 4
- Laboratory: Check for anemia and hypoxemia
The guideline framework for managing infusion reactions with alemtuzumab indicates that serious reactions occur in 3% of patients, with dyspnea being a recognized symptom 5.
Management Algorithm
For Grade 3/4 reactions (which DAH represents):
- Immediately stop the alemtuzumab infusion 5
- Provide aggressive supportive care:
- Rule out infection through BAL cultures (bacterial, viral, fungal) 3, 6
- Do NOT resume alemtuzumab - this is a serious reaction requiring permanent discontinuation 5
Prognosis and Key Points
The prognosis is generally excellent with appropriate management:
- All multiple sclerosis patients with known outcomes showed complete recovery 1
- Symptoms typically resolve within days to weeks after discontinuation 2, 3
- CT findings normalize within 1-4 weeks 2, 3
Critical caveats:
- Fatal cases have been reported in transplant patients, particularly those with Alport syndrome 6, 4, though MS patients appear to have better outcomes
- This complication may be under-recognized and under-reported 3
- The European Medicines Agency has included DAH in their safety reassessment of alemtuzumab 1
Differential Considerations
While DAH is the primary concern, also consider:
- Cytomegalovirus pneumonitis (common with alemtuzumab's profound immunosuppression)
- Bacterial/fungal pneumonia (though less likely to cause hemoptysis acutely)
- Pulmonary edema (reported as grade 3 adverse event) 7
However, the combination of hemoptysis with dyspnea occurring during/shortly after the third infusion makes DAH the most likely diagnosis requiring urgent evaluation 1, 2, 3.